BioMedNewsBreaks

FridayMar 17, 2023 10:40 am

BioMedNewsBreaks — HeartBeam Inc. (NASDAQ: BEAT) Releases Q4, FY 2022 Financial Report, Corporate Updates

HeartBeam (NASDAQ: BEAT), a cardiac technology company that has developed the first and only 3D-vector electrocardiogram (VECG) platform for heart attack detection anytime, anywhere, is reporting its operational and financial results for the fourth quarter and full year, ended Dec. 31, 2022. The company has also scheduled an earnings call and webcast for today at 4:30 p.m. ET to discuss the report. A highlight of the report includes the company’s strategic acquisition of LIVMOR assets, including its FDA-cleared Halo+(TM) Atrial Fibrillation Detection System and physician-prescribed integrated patient care platform, three U.S. patents, business contracts and relationships as well as all…

Continue Reading

ThursdayMar 16, 2023 3:44 pm

BioMedNewsBreaks – BiondVax Pharmaceuticals Ltd. (NASDAQ: BVXV) CEO to Present at BIO-Europe Spring

BiondVax (NASDAQ: BVXV), a biotechnology company focused on developing, manufacturing and commercializing innovative immunotherapeutic products primarily for the treatment of infectious and autoimmune diseases, today announced that its CEO Amir Reichman will be presenting in-person at the 17th annual BIO-Europe Spring. The event is slated to take place from March 20–22, 2023, in Basel, Switzerland, and draw over 2,800 executives from biotech, pharma and finance companies to engage in 15,000+ one-to-one meetings. Reichman’s presentation will begin at 11:30 a.m. on Tuesday, March 21, and focus on recent successful preclinical in vivo results of BiondVax’s innovative inhaled COVID-19 treatment and additional…

Continue Reading

WednesdayMar 15, 2023 1:51 pm

BioMedNewsBreaks – Silo Pharma Inc. (NASDAQ: SILO) Announces Positive Results from IND-Enabling Toxicology Study of SP-26

Silo Pharma (NASDAQ: SILO), a developmental stage biopharmaceutical company focused on merging traditional therapeutics with psychedelic research, today announced that it has achieved positive results for its toxicology study of SP-26, its novel time-released, dosage-controlled formulation of ketamine. In collaboration with Experimur, a Frontage Laboratories company, Silo Pharma tested SP-26 in a toxicology and tolerability study in mini pigs using an ascending (descending) dosing regimen in advance of initiating clinical studies. “Today’s positive results are an important step as we move closer to achieving all needed components to plan human trials of SP-26.” said Eric Weisblum, chief executive officer of…

Continue Reading

TuesdayMar 14, 2023 1:25 pm

BioMedNewsBreaks — HeartBeam Inc. (NASDAQ: BEAT) Acquires LIVEMOR Assets

HeartBeam (NASDAQ: BEAT), a cardiac technology company that has developed the first and only 3D-vector electrocardiogram (VECG) platform for heart attack detection anytime, anywhere, has acquired substantially all assets from LIVMOR, a digital health solutions company. Specifically, LIVMOR offers a patient-engaging remote monitoring system of critical physiological biomarkers. The acquisition allows HeartBeam to extend its reach with LIVEMOR’s FDA-cleared Halo+(TM) Atrial Fibrillation Detection System and its physician-prescribed integrated patient-care platform. The acquisition gives HeartBeam full ownership of the world’s first FDA-cleared prescription wearable for continuous cardiac rhythm monitoring. HeartBeam and LIVMOR partnered earlier this year to build a HeartBeam-branded version…

Continue Reading

TuesdayMar 14, 2023 12:46 pm

BioMedNewsBreaks – FSD Pharma Inc. (NASDAQ: HUGE) (CSE: HUGE) (FRA: 0K9A) Engages ShareIntel to Investigate Possible Naked Short Selling of Its Stock

FSD Pharma (NASDAQ: HUGE) (CSE: HUGE) (FRA: 0K9A), a biopharmaceutical company dedicated to building a portfolio of innovative assets and biotech solutions for the treatment of challenging neurodegenerative, inflammatory and metabolic disorders, today announced that it has renewed the service agreement with ShareIntel-Shareholder Intelligence Services LLC (www.ShareIntel.com). Under the agreement, ShareIntel will assist in ongoing investigations related to suspected naked short selling of FSD Pharma’s common stock. “Our shareholders can rest assured that we have heard their concerns. We are acting appropriately with all tools at our disposal to identify any nefarious perpetrators. We, as fervent advocates for naked short…

Continue Reading

MondayMar 13, 2023 2:35 pm

BioMedNewsBreaks – HeartBeam Inc. (NASDAQ: BEAT) On Track to Advance Innovative Products

HeartBeam (NASDAQ: BEAT) is a cardiac technology company dedicated to finding effective ways to detect heart attacks earlier than ever before. “The company has two patented products in development: HeartBeam AIMI(TM), software for acute care settings that provides a 3D comparison of baseline and symptomatic 12-lead ECG to identify a heart attack more accurately; and HeartBeam AIMIGo(TM), the first and only credit-card-sized 12-lead output ECG device coupled with a smartphone app and cloud-based diagnostic software system to facilitate remote heart attack detection,” a recent article reads. “Although HeartBeam AIMI and HeartBeam AIMIGo have not yet been cleared by the U.S.…

Continue Reading

MondayMar 13, 2023 11:52 am

BioMedNewsBreaks – InMed Pharmaceuticals Inc. (NASDAQ: INM) Peer-Reviewed Study Results Published

InMed Pharmaceuticals (NASDAQ: INM), a leader in the pharmaceutical research, development and manufacturing of rare cannabinoids and cannabinoid analogs, has announced that results of its study have been published in the “International Journal of Molecular Sciences.” The study was designed to evaluate the anti-inflammatory effects of rare cannabinoids and their potential application for the treatment of skin conditions, including atopic dermatitis, psoriasis, pruritus and acne. The study is titled “Rare Phytocannabinoids Exert Anti-Inflammatory Effects on Human Keratinocytes via the Endocannabinoid System and MAPK Signalling Pathway.” According to the announcement, study results demonstrate the therapeutic potential of rare cannabinoids in the…

Continue Reading

MondayMar 13, 2023 11:36 am

BioMedNewsBreaks – CNS Pharmaceuticals Inc. (NASDAQ: CNSP) Announces It Has No Exposure to Silicon Valley Bank Issues

CNS Pharmaceuticals (NASDAQ: CNSP) is a biopharmaceutical company specializing in the development of novel treatments for primary and metastatic cancers in the brain and central nervous system. The company today announced that it is aware that the Federal Deposit Insurance Corp. has taken control of Silicon Valley Bank (“SVB”) due to liquidity concerns. CNS Pharmaceuticals does not hold any deposits or investments at SVB. To view the full press release, visit https://ibn.fm/SPCyI About CNS Pharmaceuticals Inc. CNS Pharmaceuticals is a clinical-stage pharmaceutical company developing a pipeline of anti-cancer drug candidates for the treatment of primary and metastatic cancers of the…

Continue Reading

FridayMar 10, 2023 1:18 pm

BioMedNewsBreaks – India Globalization Capital Inc. (NYSE American: IGC) Bringing Hope for Alzheimer’s Treatment

India Globalization Capital (NYSE American: IGC) is developing a cannabis-based investigational drug that is being tested for the first time ever on humans in an FDA-approved study. This is groundbreaking work that established its commitment as a pioneer in the treatment of Alzheimer’s disease, given there are no currently FDA-approved drugs to treat Alzheimer’s patients. “The company is developing its proprietary treatment, IGC-AD1, hoping to provide relief to the 55 million people worldwide struggling with agitation in dementia that results from Alzheimer’s. IGC is focused on revolutionizing the treatment of Alzheimer’s with its game-changing drug candidate. In phase 1 studies,…

Continue Reading

ThursdayMar 09, 2023 12:30 pm

BioMedNewsBreaks – CNS Pharmaceuticals Inc. (NASDAQ: CNSP) Enrolls First Patient in Switzerland in Potentially Pivotal Berubicin Trial

CNS Pharmaceuticals (NASDAQ: CNSP), a biopharmaceutical company specializing in the development of novel treatments for primary and metastatic cancers in the brain and central nervous system, today announced that the first patient in Switzerland has been enrolled in the company’s ongoing global trial. The potentially pivotal trial is focused on evaluating Berubicin for the treatment of recurrent glioblastoma multiforme (“GBM”), an aggressive and incurable form of brain cancer. “The active patient enrollment we continue to build across our clinical trial sites in Europe is incredibly encouraging. Our team is laser focused on getting additional clinical trial sites online so that…

Continue Reading